Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus R-GDP with or without maintenance selinexor in relapsed or refractory diffuse large B-cell lymphoma
MOH_2020-06-14_009027Phase 3Active, not recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of selinexor in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Karyopharm Therapeutics Inc. Started Apr 2020; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2020-06-14_009027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-14_009027.